pralatrexate

Term ID

CHEBI:71223

Synonyms

(2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid
(2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid
10-Propargyl-10-deazaaminopterin
Folotyn
HSDB 7786
N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid
pralatrexate
pralatrexato
pralatrexatum

Definition

A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.

References

cas:146464-95-1
drugcentral:4117
kegg.drug:D05589
patent:US2005267117
patent:US2011190305
patent:US6028071
patent:US6323205
patent:WO2007023243
pubmed:20622807
pubmed:20669794
pubmed:20702104
pubmed:20739433
pubmed:21179031
pubmed:21245435
pubmed:21417858
pubmed:21591544
pubmed:21726160
pubmed:21841501
pubmed:21939422
pubmed:21956523
pubmed:22076116
pubmed:22343388
pubmed:22362328
pubmed:22394596
pubmed:22457602
pubmed:22534814
pubmed:22542448
pubmed:22789917
pubmed:22921318
pubmed:23008944
pubmed:23032692
pubmed:23040436
pubmed:23115213
reaxys:6624234
wikipedia.en:Pralatrexate

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from pralatrexate

Phenotype where environments contain pralatrexate

Phenotype modified by environments containing pralatrexate

Phenotype affecting pralatrexate

Human Disease Model